Clinical Research Directory
Browse clinical research sites, groups, and studies.
Home High-Flow Nasal Cannula vs. Noninvasive Ventilation for Stable Chronic Respiratory Failure
Sponsor: Wonju Severance Christian Hospital
Summary
The goal of this clinical trial is to compare the effects of home high-flow nasal cannula (HFNC) therapy and noninvasive ventilation (NIV) in patients with stable chronic hypercapnic respiratory failure. The main questions it aims to answer are: * Does HFNC or NIV reduce blood carbon dioxide levels more effectively? * How well do patients tolerate and adhere to each therapy? * Are there differences in oxygen saturation, respiratory rate, and quality of life between the two treatments? Participants Will: * Use either HFNC (myAirvo2®) or NIV (Trilogy Evo®) every night for at least 4 hours over a 6-week period. * Visit the hospital for checkups and arterial blood gas tests at the end of each 6-week period. * Switch to the alternate device after six weeks as part of the crossover study design. * Have their device usage recorded and analyzed.
Official title: Comparison of the Effects of Home High-Flow Nasal Cannula Therapy and Noninvasive Ventilation in Patients With Stable Chronic Hypercapnic Respiratory Failure
Key Details
Gender
All
Age Range
40 Years - Any
Study Type
INTERVENTIONAL
Enrollment
38
Start Date
2025-03
Completion Date
2026-06
Last Updated
2025-03-12
Healthy Volunteers
No
Interventions
High-Flow Nasal Cannula
To compare the effects of NIV (Trilogy Evo®) and HFNC (myAirvo2®) in patients with chronic hypercapnic COPD.
Noninvasive Ventilation
to compare the effects of NIV (Trilogy Evo®) and HFNC (myAirvo2®) in patients with chronic hypercapnic COPD
Locations (1)
Wonju Severance Christian Hospital
Wŏnju, Gangwondo, South Korea